Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-18038683 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNJ-18038683 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Escitalopram | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Form= capsule, route= oral use. Administration once daily for 8 weeks. |
| Escitalopram | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week. |
| JNJ-18038683 | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week. |
Inclusion Criteria: * Diagnosed with moderate to severe major depressive disorder * Willing to use acceptable methods of birth control throughout the study and for 3 months after * In good general health Exclusion Criteria: * No history or current diagnosis of other psychiatric conditions such as...
Top 20 of 31 competitors
JNJ-18038683 is an investigational small molecule developed by Johnson & Johnson for Major Depressive Disorder. It is a Phase 2 psychiatry candidate and has not been approved for any use. It was studied in a single completed placebo-controlled trial in adults with moderate to severe depression.
JNJ-18038683 targets HTR7, the serotonin 5-HT7 receptor, and acts as an antagonist. By blocking this receptor, the compound was designed to act on serotonin signaling pathways relevant to mood regulation. This mechanism distinguishes it from standard monoamine reuptake inhibitors used in depression.
JNJ-18038683 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The compound is an internal psychiatry asset studied for Major Depressive Disorder.
JNJ-18038683 is in Phase 2 development for Major Depressive Disorder. It is investigational and has not been approved by the FDA or any other regulator. Its only recorded trial, NCT00566202, has been completed, and no trials are currently active.
JNJ-18038683 was evaluated in one Phase 2 trial, NCT00566202, titled a safety and effectiveness study in patients with moderate to severe depression. The trial was completed, enrolled 67 participants, was randomized, double blind, and placebo controlled, and was conducted in the United States.